This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Azithromycin ocular


Eye drops containing azithromycin (preservative free)

Drugs List

  • azithromycin 15mg/g eye drops preservative-free
  • AZYTER 15mg/g eye drops
  • Therapeutic Indications


    Conjunctivitis - infective
    Trachoma: treatment



    Instil one drop into the affected eye(s) twice a day, morning and evening, for three days.


    Instil one drop into the affected eye(s) twice a day, morning and evening, for three days.


    Instil one drop into the affected eye(s) twice a day, morning and evening, for three days.


    This treatment is not intended to be used as prophylactic treatment of bacterial conjunctivitis in neonates. Ocular infection in neonates caused by Chlamydia trachomatis or Neisseria gonorrhoeae may require systemic treatment - consult local guidelines.


    Wearing of contact lenses

    Precautions and Warnings

    History of progenitor cell transplantation

    Advise patient blurred vision may affect ability to drive/operate machinery
    Advise patient not to use for 15 mins after applying any other ocular agent
    Discard any unused portion
    To reduce systemic absorption compress lacrimal sac during administration
    If no clinical response after 2-3 days consider alternative treatment
    Discontinue if allergic reaction occurs
    Maximum treatment 3 days
    Advise patient to avoid touching the eye/other surfaces with container tip
    Contact lenses should not be worn during treatment

    Pregnancy and Lactation


    The manufacturer notes that this medication can be used during pregnancy as no effect on pregnancy is anticipated, since systemic exposure to azithromycin is negligible.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    The manufacturer notes that breast feeding is possible during treatment with this medication. Limited data indicates that azithromycin is excreted in breast milk but, considering the low dose and the low systemic availability, the doses taken by the neonate are negligible.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Allergic conjunctivitis
    Blurred vision (transient)
    Burning and stinging of the eyes
    Conjunctival hyperaemia
    Eyelid eczema
    Eyelid erythema
    Eyelid oedema
    Hypersensitivity reactions
    Increased lacrimation
    Ocular allergy
    Ocular discomfort
    Ocular pruritus
    Sensation of foreign body in eye
    Sticky sensation of the eye


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2013

    Reference Sources

    British National Formulary, 65th Edition (March - September 2013) Pharmaceutical Press, London.

    BNF for Children (2012-2013) Pharmaceutical Press, London.

    Summary of Product Characteristics: Azyter 15mg/g eye drops. Spectrum Thea Pharmaceuticals Limited. Revised January 2013.

    HPRA Safety Notice May 2018
    Available at:
    Last accessed: 23 October 2018

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.